SuperworthSeres Therapeutics MCRB
- Market cap
- $20.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 11.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.9M
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −246.9%
Seres Therapeutics trades at 11.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.9M over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $310K−91% | $64K−93% | $0 | $0 | $0 | $0 | $0 | $0 | $351K | $438K | $358K | $736K | |
| R&D | $25.2M−42% | $26.8M−42% | $19.5M−56% | $15.8M−66% | $16.5M−35% | $12.8M−52% | $11.8M−39% | $12.9M−18% | $12.6M−23% | $11.7M−9% | $13.2M+12% | $9.1M−29% |
| SG&A | $19.4M+6% | $17.2M−23% | $14.9M−34% | $13.1M−53% | $12.7M−35% | $12.5M−28% | $11.9M−20% | $10.3M−22% | $9.5M−25% | $7.5M−40% | $8.1M−32% | $7.1M−31% |
| −$44.6M−25% | −$39.5M−42% | −$34.4M−51% | −$28.9M | −$29.2M−35% | −$28.8M−27% | −$27.2M−21% | −$24.9M−14% | −$22.5M−23% | −$19.4M−33% | −$20.9M−23% | −$21.3M−15% | |
| Interest expense | $0 | $4M+114% | $618K−68% | $0 | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a |
| Net income | −$47.9M−20% | −$41.2M−40% | −$40.1M−44% | −$32.9M | $88.8M | −$15.6M−62% | $32.7M | −$19.9M−40% | $8.2M−91% | −$15.3M−2% | −$19.9M | $4.6M |
| −$7.40−25% | −$6.40−42% | −$5.49−52% | −$4.34 | $11.63 | −$1.83−71% | $3.75 | −$2.27−48% | $0.94−92% | −$1.66−9% | −$2.08 | $0.47 | |
| 6.4M+5% | 6.5M+4% | 7.3M+16% | 7.6M+17% | 7.6M+19% | 8.6M+32% | 8.7M+19% | 8.7M+15% | 8.8M+15% | 9.2M+8% | 9.6M+10% | 9.7M+12% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
R&D: Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 12 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Seres Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MCRBSeres Therapeutics | $20.8M | n/m | 22.6× | 11.0× | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Seres Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .